Tvardi Therapeutics (NASDAQ:TVRD) Releases Earnings Results, Misses Expectations By $0.04 EPS

Posted by Francis Steltz on Aug 15th, 2026

Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) posted its earnings results on Friday. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04), FiscalAI reports.

Tvardi Therapeutics Stock Up 7.3%

Shares of Tvardi Therapeutics stock traded up $0.13 on Friday, reaching $1.90. The company’s stock had a trading volume of 345,662 shares, compared to its average volume of 513,662. The company has a market capitalization of $17.82 million, a P/E ratio of -0.61 and a beta of 0.39. Tvardi Therapeutics has a 52-week low of $1.50 and a 52-week high of $43.65. The stock has a 50-day moving average price of $2.49 and a 200-day moving average price of $3.19.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Piper Sandler upgraded Tvardi Therapeutics from a “neutral” rating to an “overweight” rating and set a $13.00 price objective on the stock in a research report on Wednesday, July 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Wednesday, July 8th. UBS Group upgraded shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price for the company in a research note on Wednesday, July 8th. Wall Street Zen downgraded shares of Tvardi Therapeutics to a “strong sell” rating in a report on Saturday, July 18th. Finally, Raymond James Financial raised shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Tvardi Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Read Our Latest Stock Report on Tvardi Therapeutics

Institutional Investors Weigh In On Tvardi Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TVRD. JPMorgan Chase & Co. purchased a new position in Tvardi Therapeutics during the second quarter valued at $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Tvardi Therapeutics during the 2nd quarter worth about $43,000. Headlands Technologies LLC acquired a new position in shares of Tvardi Therapeutics during the 2nd quarter worth about $80,000. New York State Common Retirement Fund purchased a new position in Tvardi Therapeutics in the 2nd quarter valued at about $92,000. Finally, Squarepoint Ops LLC purchased a new position in Tvardi Therapeutics in the 3rd quarter valued at about $318,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

(Get Free Report)

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.